Dachaigh › Cancer Prostatach Seasmhach ri Castration
Sgrùdaidhean clionaigeach Cancer Prostatach Seasmhach ri Castration a’ fastadh anns na SA
Tha 18 sgrùdaidhean airson Cancer Prostatach Seasmhach ri Castration a’ fastadh phàirtichean aig làraichean air feadh nan Stàitean Aonaichte.
Bailtean leis na sgrùdaidhean as motha
- Los Angeles, CA8 sgrùdaidhean
- New York City, NY7 sgrùdaidhean
- Seattle, WA6 sgrùdaidhean
- Houston, TX6 sgrùdaidhean
- Boston, MA5 sgrùdaidhean
- Pittsburgh, PA4 sgrùdaidhean
- Philadelphia, PA4 sgrùdaidhean
- Queens, NY4 sgrùdaidhean
- Mountain View, CA3 sgrùdaidhean
- Cincinnati, OH3 sgrùdaidhean
- Nashville, TN3 sgrùdaidhean
- Dallas, TX3 sgrùdaidhean
- Minneapolis, MN3 sgrùdaidhean
- Baltimore, MD3 sgrùdaidhean
- St. Louis, MO3 sgrùdaidhean
- San Francisco, CA3 sgrùdaidhean
- Myrtle Beach, SC3 sgrùdaidhean
- Grand Rapids, MI3 sgrùdaidhean
- Arlington, VA3 sgrùdaidhean
- San Diego, CA3 sgrùdaidhean
- Metairie, LA3 sgrùdaidhean
Le stàit
- California11 sgrùdadh
- Connecticut3 sgrùdaidhean
- Florida5 sgrùdaidhean
- Illinois3 sgrùdaidhean
- Louisiana3 sgrùdaidhean
- Maryland3 sgrùdaidhean
- Massachusetts5 sgrùdaidhean
- Michigan7 sgrùdaidhean
- Minnesota4 sgrùdaidhean
- Missouri3 sgrùdaidhean
- Nebraska3 sgrùdaidhean
- New Jersey4 sgrùdaidhean
- New York8 sgrùdaidhean
- North Carolina4 sgrùdaidhean
- Ohio4 sgrùdaidhean
- Oregon3 sgrùdaidhean
- Pennsylvania5 sgrùdaidhean
- South Carolina4 sgrùdaidhean
- Tennessee5 sgrùdaidhean
- Texas7 sgrùdaidhean
- Virginia4 sgrùdaidhean
- Washington6 sgrùdaidhean
Sgrùdaidhean air an ùrachadh o chionn ghoirid
Teacsa sgrùdaidh oifigeil (Beurla)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 25 Sult 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 24 Sult 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 10 Sult 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
A’ fastadhÌre 1
Aoisean 18 gu 100 · Fir · Air ùrachadh 13 Lùna 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 10 Lùna 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 115 · Fir · Air ùrachadh 16 Iuch 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 115 · Fir · Air ùrachadh 16 Iuch 2026 · NCT07677254A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 29 Cèit 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 6 Cèit 2026 · NCT04868604Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 13 Gibl 2026 · NCT04337580Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 13 Gibl 2026 · NCT06190899Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 21 Samh 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Fir · Air ùrachadh 27 Samh 2024 · NCT06706921Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.